A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/55 (2006.01) A61K 31/27 (2006.01) A61K 31/365 (2006.01) A61K 31/40 (2006.01) A61K 31/44 (2006.01) A61K 31/47 (2006.01) A61K 31/66 (2006.01) A61P 25/18 (2006.01)
Patent
CA 2103022
The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for counteracting the sedative, hypnotic or respiratory depressive effects of benzodiazepines; substantially without interfering with, the anxiolytic, antipsychotic, anticonvulsant; and muscle relaxant activity of benzodiazepines, especially, the benzodiazepines used for treatment of diseases where the sedative; hypnotic or respiratory depressive effects are undesirable, such as diseases selected from the group consisting of anxiety, anxiety neurosis; anxiety reactions, panic reactions, schizophrenia; affective or schizoaffective type schizophrenia, borderline psychosis, agitating endogene depressions, hyperactivity in children, and muscle spasms; the use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of schizophrenia, in particular affective or schizoaffective type shizophrenia. The acetyl cholinesterase is preferably one that acts substantially selectivity at nicotinic receptor sites, and which has selectively for acetyl cholinesterase opposed to butyryl cholinesterase, e.g. galanthamine or a galanthamine derivative.
Snorrason Ernir
Fetherstonhaugh & Co.
Snorrason Ernir
LandOfFree
Improvements in benzodiazepine treatment by cholinesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Improvements in benzodiazepine treatment by cholinesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improvements in benzodiazepine treatment by cholinesterase... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2026405